Essential Partners’s Gyre Therapeutics GYRE Stock Holding History

Essential Partners’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1	Closed	-$7	–	2915
2026 Q2	$7	Sell	1 -3	-75%	-$20	﹤0.01%	2850
2026 Q1	$28	Buy	+4	New	+$31	﹤0.01%	2812
2025 Q3	–	Sell	-2	Closed	-$15	–	2716
2025 Q2	$15	Buy	+2	New	+$17	﹤0.01%	2237

Other funds holding GYRE

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners's GYRE Position: Q3 2026 in Review

Essential Partners sold out of Gyre Therapeutics (GYRE) in Q3 2026, closing a stake of 1 share — an estimated $7 sold.

Essential Partners first reported a position in GYRE in Q2 2025 and held it in 3 quarters. The position peaked at $28 in Q1 2026. 4 funds tracked by Wall St. Rank hold GYRE as of Q3 2026.

Essential Partners reported no remaining Gyre Therapeutics position as of Q3 2026 after selling out during the quarter.
Essential Partners sold 1 Gyre Therapeutics share in Q3 2026, an estimated $7.
Essential Partners first reported a position in Gyre Therapeutics in Q2 2025 and held it in 3 quarters.
Essential Partners's Gyre Therapeutics position peaked at $28 in Q1 2026.
4 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.